Global vaccine safety initiative: 2018 meeting report
World Health Organization.
Geneva; World Health Organization; 2019. (WHO/MVP/EMP/SAV/2019.01).
em Inglês | WHOLIS | ID: who-280125
Documentos relacionados
Preventive Pharmacovigilance: timely and precise prevention of adverse events through person-level patient screening and dose-level product surveillance.
Cryptic vaccine-associated adverse events: The critical need for a new vaccine safety surveillance paradigm to improve public trust in vaccines.
The impact of regulation changes in the spontaneous reporting system for vaccines on reporting trends and signal detection in Japan.
Detection of Vaccine Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting System.
Evolving pharmacovigilance requirements with novel vaccines and vaccine components.
Global burden of vaccine-associated alopecia, 1979-2023: a comprehensive analysis of the international pharmacovigilance database.
Which pharmacovigilance for vaccines?
Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres.
Imprecision in vaccine adverse event reporting and a methodological analysis of reporting systems to improve pharmacovigilance and public health.
Landscape analysis of pharmacovigilance and related practices among 34 vaccine manufacturers' from emerging countries.